Health
New pancreatic cancer pill could reshape treatment as early trial results stun researchers
FDA fast-tracks pancreatic cancer drug daraxonrasib
Family and emergency medicine physician Dr. Janette Nesheiwat discusses how artificial intelligence could help detect pancreatic cancer earlier and the FDA fast-tracking the drug daraxonrasib on ‘Fox Report.’
NEWYou can now listen to Fox News articles!
A new drug for pancreatic cancer is showing promise in early testing.
Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial — the first time it was tested in people — to evaluate both its safety and effectiveness.
The clinical trial, led by the Dana-Farber Cancer Institute and published in The New England Journal of Medicine, tested the drug in 168 patients with advanced pancreatic cancer whose tumors had mutations in the RAS gene. All study participants had previously received at least one chemotherapy treatment.
6 THINGS TO KNOW ABOUT PANCREATIC CANCER AFTER FORMER SENATOR’S DIAGNOSIS
The drug is designed to block multiple active cancer signals that help tumor cells grow. This is especially important because more than 90% of pancreatic cancers carry these harmful mutations, researchers said.
Existing and older drugs that target RAS mutations only work on certain types that are uncommon in pancreatic cancer, such as KRAS mutations.
Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial to evaluate its safety and effectiveness. (iStock)
At the 300-milligram dose — the amount that will be used in larger phase 3 trials — about 30% of patients saw a positive response, researchers noted. Overall, about 90% of patients had their cancer either shrink or stop getting worse.
DEADLY CANCER TYPE LINKED TO OBESITY AND HIGH STRESS LEVELS
There were some side effects reported — most commonly rash, mouth inflammation, nausea and diarrhea.
Lead investigator Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, commented in a press release statement that this development could change the future of cancer care.
About 90% of patients treated with the drug experienced disease control, meaning their cancer was reduced or stabilized. (iStock)
“If supported by data from future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer,” he said.
RISK OF DEADLY CANCER TRIPLES WITH HIDDEN MOUTH BACTERIA, STUDY FINDS
“This trial provides the first published data showing the safety and broad activity of a RAS(ON) multi-selective inhibitor in pancreatic cancer,” Wolpin went on. “If it proves effective in larger clinical trials, it would signify a substantial shift in how this disease is treated.”
In an interview with Fox News Digital, the researcher claimed that daraxonrasib represents “one of the most promising therapy advances we’ve seen in pancreatic cancer.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
This is especially significant since pancreatic cancer has had “very few effective therapies” in the past, Wolpin noted.
“The study also showed disease control in approximately 90% of patients with metastatic pancreatic cancer, which is extremely exciting,” he added.
The study does not prove daraxonrasib is superior to standard treatment of chemotherapy, researchers noted. (iStock)
Wolpin noted that while side effects were common, most patients were able to tolerate treatment with “supportive care measures, and very few patients needed to stop therapy due to side effects.”
As this was a phase 1/2 study, it does not “definitively prove” the superiority of daraxonrasib compared to chemotherapy, Wolpin added.
CLICK HERE FOR MORE HEALTH STORIES
“The study did not include a randomized control arm that directly compared daraxonrasib with chemotherapy,” he said. “That being said, the results for daraxonrasib looked substantially better than what we have seen in prior clinical trials of chemotherapy in patients with previously treated metastatic pancreatic cancer.”
It also remains unclear how the drug may perform earlier in the disease, as the trial included patients who had already received prior treatments.
“Additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” the lead investigaror sid. (iStock)
For patients and families affected by pancreatic cancer, Wolpin noted that daraxonrasib signals “real momentum” toward effective treatments, but it is still investigational and is not a cure.
“Pancreatic cancer remains a challenging disease, and additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, applauded this development in a separate interview with Fox News Digital.
“We are anxiously awaiting the upcoming plenary presentation of RASolute 302 at the ASCO meeting later this month,” said the expert, who was not involved in the study. “Greater than 90% of pancreatic cancers have activation of kRAS, which is a major factor in the development and progression of these cancers.”
“Doubling the survival time in pretreated patients is unprecedented.”
“If the full dataset results that will be reported later this month confirm what was earlier released, I believe this will be one of the most important breakthroughs in all solid tumors,” Slomovitz went on. “Doubling the survival time in pretreated patients is unprecedented.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The doctor added that the “magnitude of benefit” could “reshape the treatment landscape” and “establish a new standard of care.”
“We will need to evaluate the full dataset for efficacy and safety,” Slomovitz added. “I am more than cautiously optimistic, and I am truly excited for our patients and their families that suffer from this dreadful disease.”
NEWYou can now listen to Fox News articles!
Eliminating sugar from your diet may seem like the key to healthy eating, but research suggests it could have unintended effects on digestive health.
A study presented at ENDO 2026, the Endocrine Society’s annual meeting, suggests that a total lack of sucrose, or table sugar, may harm gut health and disrupt the body’s natural metabolism.
To explore how the total absence of dietary sugar impacts the body, researchers at the Dasman Diabetes Institute in Kuwait City conducted a 16-week study on two groups of mice. Both groups were placed on a low-fat diet, but with one critical difference.
COMMON CHEMICALS FROM FOOD ADDITIVES TO PESTICIDES MAY BE WRECKING YOUR GUT HEALTH, STUDY SAYS
One group consumed a low-fat diet that included a standard amount of sucrose, while the other group ate a low-fat diet that was completely sugar-free, according to the study’s press release.
Throughout the trial, the scientists monitored a wide variety of physiological factors, including the animals’ weight, glucose tolerance, insulin sensitivity, hormone levels, internal inflammation and the specific composition of their gut bacteria.
A total lack of dietary sugar can cause imbalances in the gut bacteria and lead to signs of fatty liver disease, even without any weight gain, researchers said. (iStock)
The study outcome suggested that completely removing sugar caused several unexpected health problems.
“Completely removing sucrose from a low-fat diet may unexpectedly disrupt gut health and promote inflammation and metabolic dysfunction,” Rasheed Ahmad, principal scientist and head of the Immunology & Microbiology Department at the Dasman Diabetes Institute, said in the release.
AMERICANS’ HIGH SUGAR CONSUMPTION PROMPTS URGENT WARNING FROM HEALTH LEADERS
Even though the mice on the sugar-free diet did not gain any extra weight compared to the control group, their internal health indicators deteriorated.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The animals that lacked sucrose developed an imbalance in their gut microbes and increased inflammation within the intestines and liver.
They also showed signs of poor glucose regulation, insulin resistance and cellular changes associated with fatty liver disease, according to the research.
Future dietary guidelines may shift away from strict, absolute sugar bans and instead focus on overall gut health through balanced nutrition. (iStock)
“The findings suggest that complete removal of sucrose from a low-fat diet may negatively affect gut microbiota and metabolic health,” Ahmad concluded.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
While the risks of high-sugar diets are well-established, the researchers noted that little attention has been given to the effects of completely eliminating sugar from low-fat meals.
Scientists say these new findings highlight that dietary carbohydrates play a valuable role in supporting balance between the immune system and the gut microbiome.
Completely cutting sucrose from a low-fat diet can unexpectedly trigger gut inflammation and disrupt the metabolism, experts say. (iStock)
Because this research was conducted on mice over a relatively short 16-week period, further clinical trials are necessary to determine whether a completely sugar-free diet causes the same gut and liver inflammation in humans.
CLICK HERE FOR MORE HEALTH STORIES
Additionally, the study focused specifically on removing sucrose from low-fat meals, meaning the results might not apply to people eliminating sugar while following higher-fat or ketogenic eating plans, the researchers noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The team believes that future dietary guidelines may shift away from strict, absolute sugar restrictions and instead place a greater emphasis on maintaining a diverse, healthy population of gut bacteria through balanced nutrition.
“In the long term, these findings could help improve strategies for preventing and managing metabolic disorders, fatty liver disease and chronic inflammatory conditions,” Ahmad said.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A cure for cancer could be on the horizon in the next decade, according to experts.
During the WSJ Leadership Institute CEO Summit in London last week, Johnson & Johnson Chairman and CEO Joaquin Duato reflected on the pharmaceutical company’s projections on the future of cancer treatment.
In the next 10 years, the goal is to “try to eliminate cancer,” Duato shared.
NEW CANCER VACCINE DELIVERS STUNNING RESULT AGAINST ONE OF THE DEADLIEST SKIN CANCERS
“That’s a high goal, and we are already making significant progress in certain cancers,” he said.
Duato used multiple myeloma as an example, noting that the life expectancy is currently 10 years, when it was previously “only single years.”
Joaquin Duato, chairman and CEO of Johnson and Johnson, speaks at the Punchbowl News Conference at Union Station on March 10, 2026, in Washington, DC. (Heather Diehl/Getty Images)
“We have treatments now that utilize your own immune system to attack the cancer,” he said at the summit. “For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission. That [is] spectacular.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“When patients see that, they cannot believe that because they have been coming to the hospital every week [for] a decade, having multiple therapies.”
The goal is to “try to eliminate cancer” in the next 10 years, the pharmaceutical executive said. (iStock)
According to Duato, Johnson & Johnson is working to understand the biology of cancer growth and to formulate new technologies to address it.
“It’s realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases,” he predicted.
CLICK HERE FOR MORE HEALTH STORIES
“Cancer is an important thing – I cannot think about anybody who has not been touched by cancer,” he went on. “But there are many other opportunities for us to actually advance science, to address very important social problems.”
Duato called out dementia as another “important problem” in need of a solution.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
He predicted that life expectancy, which has risen steadily over the past century, will continue to increase as longevity technologies and solutions advance, improving quality of life along the way.
Duato commented that J&J has been optimistic about the role artificial intelligence will play in the future of healthcare, calling it a “force multiplier.”
Biomarkers and AI can help with the earlier diagnosis of cancer, as well as a more advanced and personalized approach to surgery, a doctor noted. (iStock)
Fox News senior medical analyst Dr. Marc Siegel agreed with Duato’s outlook on the future of cancer care, noting that certain cancers will turn into chronic diseases while others will find outright cures.
“Advances [will be] based on the use of AI to help guide targeted treatments with expanding knowledge of cancer mutations and how to target them,” he predicted, speaking to Fox News Digital.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Siegel added that biomarkers and AI can help with earlier diagnoses, as well as a more advanced and personalized approach to surgery.
J&J recently acquired Firefly Bio, a biotech firm that produces drugs that enter cancer cells to “target certain proteins that contain difficult to treat gene mutations,” the doctor added.
-
News23 minutes agoGOP Rep. Tom Kean, missing from Congress for months, set to return on June 30
-
Los Angeles, Ca2 hours agoComedian to face charges in first case from L.A. County tax fraud unit
-
Detroit, MI2 hours agoDetroit archdiocese releases last proposed parish Mass stoppages. List hits 90
-
San Francisco, CA2 hours ago
Morning Report: McKivitz Highlights Special Connection to SF 🗞️
-
Dallas, TX2 hours agoFOX’s Kasper Schmeichel compares England to Dallas Cowboys, so who are their other sports analogs?
-
Miami, FL2 hours agoMiami ‘At the Top’ for Star In-State 2028 Running Back
-
Boston, MA2 hours ago
Boston Bruins are retiring Patrice Bergeron’s No. 37 next season
-
Denver, CO3 hours agoBroncos make decision on tryout quarterback, sign 2 players
